

Aberystwyth University

Experimental Models for the Analysis of IL-10 Function

Wynn, Thomas A.; Aliberti, Julio; Hoffmann, Karl F.; Jankovic, Dragana; Feng, Carl G.; Kullberg, Marika C.; Sher, Alan

Published in:
Interleukin-10

Publication date:
2006

Citation for published version (APA):

Wynn, T. A., Aliberti, J., Hoffmann, K. F., Jankovic, D., Feng, C. G., Kullberg, M. C., & Sher, A. (2006). Experimental Models for the Analysis of IL-10 Function. In F. M. Marincola (Ed.), *Interleukin-10* Taylor & Francis. <http://hdl.handle.net/2160/5762>

General rights

Copyright and moral rights for the publications made accessible in the Aberystwyth Research Portal (the Institutional Repository) are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Aberystwyth Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Aberystwyth Research Portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

tel: +44 1970 62 2400
email: is@aber.ac.uk

CHAPTER 2

Experimental Models for the Analysis of IL-10 Function

Carl G. Feng, Julio Aliberti, Karl F. Hoffmann, Dragana Jankovic, Marika C. Kullberg, Alan Sher and Thomas A. Wynn

Abstract

This review focuses on the regulatory functions of IL-10 in the response to parasitic and bacterial infection revealed through knockout, cytokine/receptor blocking, and transgenic mouse studies. The various mechanisms that control the production and activity of IL-10 are also discussed. Studies performed over the past few years illustrate a complex and pleiotropic nature for IL-10 in host immunity. The fact that nearly every cell in the body can respond to IL-10 and multiple cells produce the cytokine likely explains this multifaceted activity. Studies conducted in experimental infectious and inflammatory diseases models have been particularly useful in defining the various regulatory activities of IL-10. Although these studies have identified many common themes for IL-10 in host immunity, they also nicely illustrate how IL-10 fine-tunes the response to individual pathogens and prevents inflammation.

Introduction

CD4⁺ T helper (Th) cells can be divided into three major subsets, Type-1, Type-2 and Th3/T regulatory (Treg), based upon the specific cytokines produced and the functional activities exhibited by each cell type. Type-1 Th cells produce interferon- γ (IFN- γ) and lymphotoxin (LT), which promote macrophage activation and the generation of cell-mediated immunity. Type-2 Th cells produce a variety of cytokines including IL-4, IL-5, and IL-13, and provide help for the maturation of B cells to immunoglobulin-secreting cells, thereby activating humoral defense mechanisms. In contrast to Th1 and Th2 cells, however, T regulatory cells represent a unique and more heterogeneous population, which can express a variety of immune suppressive factors including CTLA-4, TGF- β , and/or IL-10.

Central to the concept of T helper subset generation is the tendency for an immune response to become polarized. Thus, a Type-1 or Type-2 cytokine-producing profile will often dominate quickly during an immune response by preferentially amplifying one Th subset while down regulating the opposing response. This polarized response appears to be critical for host defense against many pathogenic organisms. Resistance to intracellular pathogens often requires a predominantly Type-1 response, while Type-2 responses are typically needed to fight extracellular parasites. A primary goal of immunological research over the past decade has been to understand the various mechanisms that influence the polarization of the immune response following infection and to exploit those mechanisms in vaccine design. Whereas a polarized response is often required to control infections, there is also a need to balance the response. The various effector molecules, particularly those associated with the Th1 pathway, are nonspecific in their action and can be detrimental if produced for too long, in excess, or in the wrong location. The potentially harmful molecules include nitric oxide (NO), reactive oxygen intermediates (ROI), IL-1, IFN- γ , and TNF, and these factors often operate in a synergistic fashion.

Therefore, it is important to produce a sufficiently potent type 1 response to provide efficient protection from infection, while at the same time producing a regulatory type 2 or immunosuppressive Treg cell response to prevent the protective response from causing damage to host tissues. Conversely, excessive Th2 response must also be dampened to prevent acute anaphylactic inflammation. The sections that follow illustrate how IL-10 regulates Th1 and Th2 response to infection.

IL-10 and Th1/Th2 Effector Choice

IL-10 was initially characterized as a Th2-specific cytokine that inhibits IFN- γ secretion by Th1 cells¹. Because IL-10 can also be produced by activated antigen presenting cells (APC) (macrophages, dendritic cells (DC) and B lymphocytes²⁻⁴) it was regarded as a candidate factor that could positively influence the development of Th2 cells and negatively regulate differentiation of Th1 cells. However, experimental data have failed to support this simplistic view of IL-10's effect on Th1/Th2 polarization. As anticipated, when primed with model antigens (Ag) or pathogens known to induce Th1-type responses, IL-10^{-/-} animals display highly augmented immune responses frequently associated with detrimental Th1-mediated pathology. For example, IL-10^{-/-} mice infected with *Toxoplasma gondii*,⁵ *Plasmodium chabaudi*,⁶ or certain strains of *Trypanozoma cruzi*,⁷ have greatly elevated levels of IFN- γ , IL-12 and TNF- α and reduced parasitemia, but substantially increased risk of death from a toxic shock-like syndrome compared to WT (WT) controls. Unexpectedly, however, IL-10^{-/-} mice also display enhanced Th2 responses when either challenged with allergens or exposed to Th2-type pathogens.⁸⁻¹⁰ Together these findings show that IL-10 acts as a general negative regulator of CD4-dependent immune responses rather than a polarizing cytokine that influences Th1/Th2 commitment.

The inhibitory effect of IL-10 stems from its ability to down-regulate antigen-presenting functions of both macrophages and DC, the primary sources of Ag/MHC complexes during T cell priming.^{11,12} The indirect influence of IL-10 on Th cells has been further supported by the analysis of IL-10R expression. IL-10R is expressed by most hematopoietic cells.¹³ However, while its expression is down-regulated on activated CD4⁺ T lymphocytes,¹⁴ activation of monocytes is associated with an increase in IL-10R levels,¹⁵ providing the molecular basis for the IL-10 responsiveness of the latter but not the former cell population.

In the context of Th effector choice, an important aspect of IL-10 effects on APC is its ability to inhibit not only the expression of MHC class II and costimulatory molecules but also the secretion of cytokines and chemokines.^{12,16} Although the latter effect of IL-10 is not selective and affects most of the soluble mediators produced by activated macrophages and DC, its primary consequence is down-regulation of the Th1 development, because many of the monokines (e.g., IL-12, IL-18, IL-23 and IL-27) are IFN- γ inducible cytokines required for optimal Th1 differentiation.¹⁷ For the same reason, IL-10-treated macrophages or DC appear to be promoting Th2 development.¹⁸ In contrast to this differential effect on Th1/Th2 differentiation, the accumulation of mature Th1 and Th2 effectors at the site of inflammation can be equally affected by IL-10 since it down-regulates the production of both CC and CXC chemokines.^{19,20} In addition to inhibiting the production of cytokines and chemokines, IL-10 also enhances the expression of their natural antagonists by increasing the expression of either decoy (e.g., IL-1RA and chemokine receptors)^{21,22} or soluble (e.g., p55 and p75 TNFR) receptors^{23,24} that in turn potentiate IL-10's down-modulatory effects on APC functions.

Different IL-10-producing DC populations (e.g., from Peyer's patches²⁵ and liver²⁶) have been associated with the development of Th2 responses. Recently, these observations have been extended by the findings that IL-10 is required for optimal development of Th2 cells by the CD8 CD11c⁺ subset of splenic DC.²⁷ However, since IL-10 may selectively induce apoptosis of CD8 α ⁺ CD11c⁺ cells,²⁷ this Th2 priming by IL-10 appears to be a result of a loss of IL-12-producing DC and a subsequent lack of Th1 differentiation. In addition, while the particular DC subsets were not analyzed, naïve and *Trichinella spiralis*-infected IL-10 knockout (KO) mice display higher number of CD11c⁺ DC in mesenteric lymph nodes when compared

to WT animals.²⁸ Autocrine IL-10 has been shown to prevent spontaneous maturation of human DC in vitro and to limit LPS and CD40-induced maturation.²⁹

While initially specifically associated with Th2 cells, the expression of IL-10 is now found in other Th subsets as well. When cultured in the presence of IL-10, murine bone marrow-derived DC promote development of IL-10⁺ CD4⁺ Treg lymphocytes.³⁰ Moreover, similar to human Th1 cells,³¹ murine Th1 lymphocytes may also coexpress IL-10. For example, “classical” murine Th1 immune responses following infection with different intracellular pathogens (e.g., *Brucella abortus*, *Borrelia burgdorferi*, *Leishmania major*, *T. gondii*) include not only IFN- γ ⁺ CD4⁺ cells but also “nonclassical” Th1 lymphocytes that concomitantly produce IFN- γ and IL-10³²⁻³⁵

Thus, although the effect of IL-10 on Th1/Th2 effector choice is indirect and very complex (Fig. 1), IL-10 and IL-10R still represent attractive therapeutic targets for the manipulation of APC function aimed at both promoting or/and suppressing development of different types of CD4-dependent immune responses.^{36,37}

IL-10 in Schistosome Infection

Like most host/helminth relationships, schistosome worms and their definitive hosts have coevolved survival strategies that maximize the transmission of parasite gametes (enclosed in the developing egg) and minimize the development of pathology in the host. While these strategies work well for the vast majority of the 200 million people currently infected with this pathogen, a small proportion of those affected will go on to develop life-threatening or severely debilitating illnesses.³⁸ Although there are many confounding factors that influence the schistosome/host equilibrium and clinical outcome, the induction of IL-10 during infection is a vital and indispensable process that limits host pathology and facilitates long-term survival of the parasite and host.




Figure 1.

Schistosome cercariae release proteases as they penetrate the skin of their definitive host – a process that leads to damage of surrounding tissues and the generation of robust innate immune defense mechanisms. However, greater than 90% of infective stage cercariae survive this process and ultimately reach the lungs.³⁹ Prostaglandins induced and released by the cercariae^{40,41} are believed to be indirectly responsible for increased schistosome survival during this critical period of infection via their effect on the host's immune system. Specifically, one prostaglandin, prostaglandin E₂ (PGE₂), up-regulates the production of keratinocyte-derived IL-10, which in turn limits the induction of anti-parasite inflammatory reactions in the skin of experimentally infected animals.⁴⁰ The production of IL-10 in skin seems to occur regardless of the parasite species used during the infection⁴² and is also observed in lymph nodes draining the skin.⁴³ Moreover, studies in vaccinated IL-10^{-/-} mice demonstrated that IL-10 dampens nearly all known anti-parasite effector mechanisms that operate during polarized Th1 and Th2 responses.⁴⁴ Finally, a recent study of *S. haematobium* infected children identified IL-10 as a major risk factor for reinfection after chemotherapy.⁴⁵ Together, the results of these studies suggest that schistosome parasites have evolved an IL-10-dependent mechanism that down-regulates the host's immune response early during infection, which maximizes their survival. However, it is also clear that IL-10 is critical to the survival of the infected host, by limiting egg-induced liver damage as infection becomes chronic.

Deposition of schistosome eggs into the intestines and liver of infected hosts induces a vigorous Th2 mediated, circumoval granulomatous response that, if not properly controlled, can lead to severe immuno-pathology.³⁸ Glycoconjugates and lipids derived from schistosome eggs⁴⁶⁻⁴⁸ drive IL-10 production from B cells,⁴⁹ other APCs⁴⁸, and Treg cells (Ref⁴⁷ and Hesse M, Piccirillo CA, Belkaid Y, Prufer J, Mentink-Kane M, Leusink M, Cheever AW, Shevach EM and Wynn TA. The pathogenesis of schistosomiasis is controlled by cooperating IL-10-producing innate effector and regulatory T cells. Submitted) possibly through a p38 protein kinase dependent signaling cascade.⁵⁰ IL-10 levels remain high even weeks after the egg-induced process is initiated and associate with global T cell hyporesponsiveness,⁵¹⁻⁵⁴ counter regulation of inflammatory Th1 cell populations,^{51,55} decreased proliferative capacity of host cells,^{53,56} and control of circumoval granulomatous responses.^{55,57,58} Together, these IL-10 dependent activities create an environment that prevents the formation of an over exuberant and potentially dangerous anti-egg inflammatory response.

Further insight into the regulatory role of IL-10 during schistosome infection has recently been uncovered through studies involving experimentally infected IL-10 deficient mice and analysis of data obtained from human immuno-epidemiological field investigations. As IL-10 is associated with the control of the granulomatous response and host cell proliferation during schistosome infection, it was suggested that this cytokine might be important for down-modulation of host circumoval immune responses during chronic infection. Nevertheless, a longitudinal study using schistosome-infected IL-10 deficient animals demonstrated that the magnitude of the granulomatous response decreases substantially between wk 8 and 16 of infection,¹⁰ suggesting that IL-10 plays only a minor role in the process of immune down-modulation. Nevertheless, further examination of the immune responses in these animals as well as double gene deficient mice (IL-10/IL-12- and IL-10/IL-4- KO) demonstrated that IL-10 critically controls Th1 and Th2 cytokine and antibody responses as well as immunopathology, especially during the acute phase of disease.^{10,59} Deficiencies in IL-10 are also associated with increased pathology in infected CBA/J mice,⁶⁰ IL-4 deficient mice,⁶¹ mice made tolerant to egg antigens,⁶² CD4⁺ T cell-depleted mice,⁶³ mice coinfecting with *S. mansoni* and *T. gondii*,⁶⁴ and in mice immunized with egg antigens and complete Freund's adjuvant.⁶⁵ Furthermore, IL-10 also plays an important role in the development of egg-induced hepatic fibrosis by regulating IL-13R α 2 expression (decoy receptor for the collagen inducing cytokine IL-13).⁶⁶ Together these studies indicate that IL-10 production during experimental schistosomiasis is important for several infection-related pathologies.⁶⁷

Can IL-10 contribute to the control of severe morbidity in human populations? To begin to answer this question, one recent study has elegantly confirmed the role of IL-10 in urinary tract morbidity during *S. haematobium* infection of children and adolescents in Kenya.⁶⁸ Here, the authors demonstrated that a low ratio of IL-10/TNF- α positively correlated with severe bladder wall pathology in the age- and infection intensity- matched case population. In another study performed on the shores of Lake Albert in Uganda, low levels of IL-10 were positively associated with increased fibrosis in children infected with *S. Mansoni*.⁶⁹ Additional studies of this type will contribute to our understanding of the role of IL-10 in human schistosomiasis and other helminth infections.^{28,70,71} Interestingly, a beneficial side effect of prolonged helminth-induced IL-10 production in chronically infected individuals is the ability of this cytokine to suppress atopy.⁷² Given the many critical functions exhibited by IL-10 in this disease, it is clear that interest on IL-10 and other IL-10 related family members⁷³ will continue to grow in the coming years.

IL-10 in Intracellular Protozoan Infection

Due to their capacity to induce vigorous pro-inflammatory cytokine production, protozoan pathogens such as *L. major*,⁷⁴ *T. cruzi*⁷⁵ and *T. gondii*^{76,77} rapidly stimulate IL-10 responses. This response quickly establishes an important equilibrium that limits damage to the host but at the same time prevents complete clearance of the organism so that transmission to new hosts can occur. Surprisingly, however, little is known about the stimuli that trigger IL-10 production in these infections or which cell types produce the cytokine. It is now widely believed that CD4⁺CD25⁺ Treg cells represent a major source of the cytokine during infection with *L. major*.^{34,78} While the mechanisms that drive APC to produce IL-10 during *L. major* infection are not completely clear, it was found that IgG bound to amastigote forms by means of Fc receptor ligation can stimulate IL-10 production.⁷⁹ In the case of *T. cruzi*, some parasite membrane-derived glycoinositolphospholipids possess anti-inflammatory activity on macrophages and DC in vitro, but this effect does not appear to be due to induction of IL-10.⁸⁰ Interestingly, while DC fail to secrete IL-10 in response to *T. gondii* stimulation, T cells, macrophages and glial cells produce significant levels of the cytokine during in vivo infections.

IL-10 was originally thought to regulate resistance to protozoan infection mostly through effector cell deactivation such as by inhibiting NO expression by macrophages^{81,82} or by immune deviation of T cell responses towards a type 2 cytokine profile.⁸³ However, when IL-10^{-/-} mice became available, this paradigm had to be modified to accommodate a wider range of effects of this cytokine during infection. *T. gondii* and *T. cruzi* infection in IL-10^{-/-} mice resulted in an enhanced Type 1 response and lower parasite burdens as expected, but also revealed a much more unpredicted outcome of excessive inflammation, which was associated with tissue destruction and a lethal shock-like syndrome characterized by over-production of IL-12, IFN- γ and TNF.^{5,7,84,85} An additional mechanism by which IL-10 can control inflammation is through direct inhibition of chemokine expression induced by the parasite.⁸⁶

L. major infection in IL-10^{-/-} mice results in complete clearance of the parasites from skin lesions, suggesting a role for this cytokine in the induction of parasite persistence.^{34,79} Belkaid and colleagues reported that CD4⁺CD25⁺ Treg cells are the major cell population secreting IL-10 and, therefore, regulating chronic persistence of leishmania parasites.⁷⁸ They hypothesized that direct inhibition of microbicidal activity by the IL-10 produced by this T cell population led to the persistence of the parasite. Nevertheless, a role for TGF- β Another immunomodulatory cytokine produced by Treg cells, has not been formally excluded. TGF- β has been shown to be associated with macrophage deactivation, inhibition of microbicidal function and proinflammatory mediators release in several models of protozoan infection.⁸⁷⁻⁹⁰

Metabolites of the arachidonic acid also constitute another group of anti-inflammatory mediators that can regulate immunity against protozoa parasite infections. PGE₂ production was reported in mice infected with *L. major* and *T. cruzi*.⁹¹⁻⁹⁴ A more direct correlation between production of PGE₂ and susceptibility to infection was observed after in vivo inhibition

of PGE₂ synthesis by treatment with cyclooxygenase inhibitors.^{91,92} Nevertheless, the most common cyclooxygenase inhibitors, such as Indomethacin were also shown to inhibit lipoxygenases,⁹⁵ a second class of enzymes that trigger the release of other immunomodulatory mediators. Leukotriene B₄ (LTB₄) is one of the products of the lipoxygenase metabolism of the arachidonic acid, its production had been reported during infection with *L. major*,⁹³ that appears to have an enhancing effect over cytokine production, independently of their anti- or pro-inflammatory profile. IL-10-independent regulation of IL-12 and IFN- γ production was also reported after stimulation of mice with an extract of tachyzoites of *T. gondii*,⁹⁶ a phenomenon called “dendritic cell paralysis”. It was found later that in vivo stimulation with this parasite extract induced the release of a 5-lipoxygenase-derived eicosanoid, lipoxin A₄ (LXA₄) and that 5-lipoxygenase deficient mice can not secrete LXA₄ or undergo dendritic cell paralysis.⁹⁷ The in vivo relevance of LXA₄-mediated control of IL-12 production was studied during infection of 5-lipoxygenase deficient mice with *T. gondii*.⁹⁸ These animals succumbed to infection around 30 days post-inoculation with a lower parasite burden, higher serum IL-12 levels and intense inflammation in the brain with elevated IL-12 production in situ.⁹⁸ However, when analyzed in parallel in an in vitro study, IL-10 but not LXA₄, was effective in blocking macrophage microbicidal function, suggesting that these mediators have related but not redundant effector pathways.

IL-10 in Mycobacterial Infection

Mycobacteria are slow-growing, facultative intracellular bacilli that primarily reside in phagocytes. The immune response to mycobacteria has been analyzed extensively in mouse models of *Mycobacterium tuberculosis*, *M. bovis* Bacillus Calmette-Guérin (BCG) and *M. avium* infections. Activation of infected macrophages and control of mycobacterial replication is critically dependent on IFN- γ produced by T lymphocytes.⁹⁹ Some bacilli, however, resist killing and survive within macrophages in the face of strong T cell responses. Although it is unclear how this latent infection is maintained, mechanisms that alter host immune responses, such as the induction of down-regulatory cytokines like IL-10 and TGF- β are thought to contribute to the persistence of mycobacterial infection. Production of IL-10 is of special interest as a possible evasion strategy because of its suppressive effects on many known immune functions required for inhibiting mycobacterial growth, including synthesis of pro-inflammatory cytokines/mediators, expression of MHC class II and costimulatory molecules.¹⁵

IL-10 is strongly induced at the sites of mycobacterial infection.¹⁰⁰⁻¹⁰² APC, such as macrophages and DC,¹⁰³⁻¹⁰⁵ as well as T lymphocytes^{106,107} are capable of producing IL-10 in response to mycobacterial infection. Interestingly, although originally described as a Th2 cytokine, IL-10 also appears to be produced in large quantities by Th1 IFN- γ -producing CD4⁺ lymphocytes during mycobacterial infection.^{108,109}

IL-10 inhibits cellular responses induced by mycobacterial infection at multiple levels. After activation with IFN- γ murine macrophages release pro-inflammatory cytokines and NO to control the intracellular growth of *M. tuberculosis* and *M. bovis*.¹¹⁰⁻¹¹³ This IFN- γ -mediated bactericidal effect, however, is inhibited in the presence of IL-10.¹¹⁴ Moreover, IL-10 prevents TNF-dependent apoptosis of *M. tuberculosis*-infected macrophages by inhibiting TNF production¹¹⁵ or by inducing the release of TNF receptor 2 that could form nonactive TNF-TNFR2 complexes.^{116,117} The induction of macrophage apoptosis may restrict mycobacterial spreading¹¹⁸ as well as facilitate antigen presentation to T cells¹¹⁹ thereby contributing to host control of the infection. Although IL-10 does not exhibit a direct suppressive effect on Th1 cells (see previous section), the cytokine may influence the T cell response to mycobacterial infection by modulating APC functions. Mycobacterium-induced IL-10 inhibits IL-12 production by DC in vitro and in vivo.^{104,105} In addition, BCG-infected, IL-10-deficient DC have been shown to migrate more efficiently to draining lymph nodes compared to cells from WT mice, suggesting that autocrine IL-10 regulates DC migration in response to BCG infection in vivo.¹⁰⁴

As noted above, since IL-10 has a major down-regulatory effect on cell-mediated immunity, it has been hypothesized that the production of this cytokine promotes the long-term survival of mycobacteria in infected hosts.¹²⁰⁻¹²² Initial studies,^{123,124} which used neutralizing antibody to block IL-10 function in vivo, in general supported this concept. However, more recent studies employing IL-10^{-/-} mice have yielded conflicting results (Table 1). For example, IL-10^{-/-} mice show increased resistance to *M. avium*¹²⁵ and in some¹²⁵⁻¹²⁷ but not all^{102,128,129} studies display transiently enhanced control of *M. tuberculosis* and BCG infection. The discrepancy between these studies possibly results from variation in the virulence of the mycobacteria, the time-points analysed and most importantly, the route of infection.

Although IL-10^{-/-} mice display only minimally enhanced resistance to mycobacterial infection, such observation does not rule out a role for IL-10 as one of several redundant mechanisms regulating host resistance to these microorganisms. It has been demonstrated that the over-expression of IL-10 in transgenic mice results in significantly impaired host resistance to *M. Tuberculosis*,¹⁰¹ BCG^{130,131} and *M. avium*¹⁰⁷ infection. Because the expression of transgenic IL-10 can be controlled by cell lineage-specific promoters, the relative effect of T cell- vs APC-derived IL-10 on the host immune response to mycobacterial infection was investigated. Over-production of IL-10 by T cells,^{101,130} macrophages¹³¹ or MHC class II expressing cells¹⁰⁷ lead to dramatically elevated bacterial burdens and impaired macrophage functions. IFN- γ responses, however, were not markedly decreased in these infected transgenic animals, suggesting normal development of Th1 effector cells. Together, these observations are consistent with the in vitro findings that IL-10 can over-ride the macrophage activation effects of IFN- γ .¹¹⁴

In conclusion, both in vivo and in vitro studies demonstrated that excessive IL-10 production can promote intracellular pathogen growth in macrophages and argue that IL-10-mediated immune down-regulation may contribute to the maintenance of latency in chronic mycobacterial infection, possibly as one of several redundant mechanisms.

Table 1. Effects of manipulation of IL-10 level on host resistance to mycobacterial infection

<i>Mycobacterium Spp.</i>	Methods	Bacterial Burdens ^a	References
<i>M. avium</i>	Anti-IL-10 ^b	Reduced	Ref. 123, 124
	IL-10 KO ^c	Reduced	Ref. 125
	IL-10 Tg ^d	Increased	Ref. 107
BCG	IL-10 KO	Unchanged	Ref. 128
	IL-10 KO	Transiently reduced	Ref. 126, 127
	IL-10 Tg	Increased	Ref. 130, 131
<i>M. tuberculosis</i>	IL-10 KO	Unchanged	Ref. 102, 129
	IL-10 KO	Transiently reduced	Ref. 125
	IL-10 Tg	Increased	Ref. 101

a. Compared to those in WT mice.

b. Treated with antibody specific for IL-10

c. IL-10 deficient mice

d. IL-10 transgenic mice

The Role of IL-10 in the Regulation of Inflammatory Bowel Disease

Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is the major chronic inflammatory disease of the intestinal tract. Although the etiology of IBD is unknown, the intestinal flora is believed to play an important role in its pathogenesis. This is perhaps best illustrated in experimental models of the disease – e.g., the IL-10^{-/-} mouse model – in which various immunodeficient animals develop intestinal inflammation when housed in conventional animal facilities, but not when reared under specific pathogen-free or germ-free conditions. (reviewed in 132)

The immune mechanisms that regulate intestinal inflammation have been extensively studied over the years, and data from the severe combined immunodeficiency (SCID) transfer model have been particularly useful in defining both pathogenic and disease-protective CD4⁺ T cell responses in IBD. In the SCID transfer model, colitis is induced in T cell-deficient SCID or Rag^{-/-} recipients by transfer of naïve CD4⁺ CD45RB^{hi} T cells.^{133,134} Cotransfer of the CD45RB^{low} memory T cell subset prevents the development of inflammation, defining a population of CD4⁺ Treg cells with disease-suppressive function.¹³⁴⁻¹³⁶ Subsequent studies have demonstrated that IL-10 plays a disease-protective role in this model as 1) systemic administration of recombinant IL-10 prevents development of CD45RB^{hi}-induced colitis, 2) anti-IL-10R treatment reverses the disease suppression mediated by the CD45RB^{low} cells, and 3) CD45RB^{low} cells from IL-10^{-/-} animals fail to protect from disease.^{137,138} Furthermore, CD45RB^{hi} cells isolated from IL-10 transgenic mice do not induce colitis in SCID recipients and these transgenic IL-10-secreting CD45RB^{hi} cells are even able to protect from colitis induced by CD45RB^{hi} cells from WT mice.¹³⁹

IL-10 clearly controls intestinal inflammation also in other models of colitis. For example, IL-10 therapy has been shown beneficial in preventing and/or partially reversing disease in the IL-10^{-/-} and trinitrobenzene sulphonic acid (TNBS) colitis models.^{140,141} Moreover, Treg cell suppression of T-cell dependent as well as T-cell independent *Helicobacter hepaticus*-triggered intestinal inflammation in Rag^{-/-} mice is reversed by anti-IL-10R treatment.^{142,143} Interestingly, administration of anti-IL-10R mAb to normal BALB/c mice leads to the induction of colitis,¹⁴⁴ arguing that IL-10 is required also in intact immunocompetent animals to maintain intestinal homeostasis. Studies from the *H. hepaticus* colitis model have further demonstrated that whereas infected IL-10^{-/-} animals develop a pathogenic Th1 type response, infected WT mice that are disease free mount an IL-10-dominated immune response against the bacterium.¹⁴⁵ These studies support the hypothesis that in immunocompetent hosts, intestinal flora induces IL-10-secreting CD4⁺ T cells that prevent pathologic immune responses towards intestinal antigens. The cellular source of the disease-protective IL-10 in most of the colitis models are indeed believed to be CD4⁺ Treg cells,^{138,142,143,145} although B cell-derived IL-10 has been reported to suppress intestinal inflammation in TCR α -deficient mice.¹⁴⁶

There are likely multiple mechanisms by which IL-10 exerts its disease-suppressive effect in IBD. Treg cells, through their production of IL-10, are known to control the expansion of colitogenic CD4⁺ T cells.^{138,142,143,147,148} Moreover, in addition to its down-regulatory effects on APC populations,^{11,12,149} IL-10 has been shown to promote the development of IL-10-secreting CD4⁺ Treg cells in vitro¹⁵⁰ and to enhance the differentiation of DC that prime such Treg cells.³⁰ Evidence that IL-10 may prevent intestinal inflammation by acting on the innate arm of the immune response comes from a report describing the development of enterocolitis in mice whose macrophages and neutrophils are rendered IL-10 unresponsive by specific disruption of the Stat3 gene.¹⁵¹ Likewise, as mentioned above, Treg cells are able to in an IL-10-dependent fashion suppress the colitis that develops in *H. hepaticus*-infected Rag^{-/-} mice on the 129SvEv background, suggesting that cells of nonT lymphocyte compartments are the targets of IL-10 activity.¹⁴³ Besides IL-10, TGF- β plays an important role in protection against colitis¹⁵²⁻¹⁵⁴. The relation between IL-10 and TGF- β in disease suppression is not yet clear, however studies in the TNBS colitis model suggest that IL-10 acts by down-regulating

the Th1 response, thereby facilitating TGF- β secretion in the host¹⁵⁵. IL-10 may also enhance TGF- β receptor type II expression and restore TGF- β responsiveness of activated T cells¹⁵⁶.

Similar to the findings in experimental models, the gut flora has been implicated in the development of IBD also in humans¹⁵⁷⁻¹⁵⁹. Moreover, while normal individuals display peripheral tolerance against resident autologous flora mediated by CD4⁺ T cells secreting IL-10 and TGF- β ¹⁶⁰ this state is broken in active IBD.¹⁶¹ In contrast to rodent models, however, systemic treatment of IBD patients with recombinant human IL-10 has thus far not been very effective, and other approaches are therefore being developed for use in humans.¹⁶² Encouraging results have been obtained from experimental models using IL-10-secreting *Lactococcus lactis* to treat IL-10^{-/-} mice as well as mice exposed to dextran sodium sulfate,¹⁶³ and a phase I clinical trial using IL-10-secreting bacteria in patients with Crohn's disease is currently underway.¹⁶² Taken together, IL-10 clearly has suppressive effects on inflammatory responses in the intestine and with improved methods for delivery this cytokine may prove beneficial as a treatment for humans with IBD.

References

1. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. *J Exp Med* Dec 1 1989; 170(6):2081-2095.
2. Shnyra A, Brewington R, Alipio A et al. Reprogramming of lipopolysaccharide-primed macrophages is controlled by a counterbalanced production of IL-10 and IL-12. *J Immunol* Apr 15 1998; 160(8):3729-3736.
3. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. *Nat Immunol* Aug 2001; 2(8):725-731.
4. Mauri C, Gray D, Mushtaq N et al. Prevention of arthritis by interleukin 10-producing B cells. *J Exp Med* Feb 17 2003; 197(4):489-501.
5. Gazzinelli RT, Wysocka M, Hieny S et al. In the absence of endogenous IL-10, mice acutely infected with *Toxoplasma gondii* succumb to a lethal immune response dependent on CD4⁺ T cells and accompanied by overproduction of IL-12, IFN- γ and TNF- α . *J Immunol* Jul 15 1996; 157(2):798-805.
6. Li C, Corraliza I, Langhorne J. A defect in interleukin-10 leads to enhanced malarial disease in *Plasmodium chabaudi* infection in mice. *Infect Immun* Sep 1999; 67(9):4435-4442.
7. Hunter CA, Ellis-Neyes LA, Slifer T et al. IL-10 is required to prevent immune hyperactivity during infection with *Trypanosoma cruzi*. *J Immunol* Apr 1 1997; 158(7):3311-3316.
8. Grunig G, Corry DB, Leach MW et al. Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis. *J Exp Med* Mar 17 1997; 185(6):1089-1099.
9. Wynn TA, Morawetz R, Scharton-Kersten T et al. Analysis of granuloma formation in double cytokine-deficient mice reveals a central role for IL-10 in polarizing both T helper cell 1- and T helper cell 2-type cytokine responses in vivo. *J Immunol* Nov 15 1997; 159(10):5014-5023.
10. Wynn TA, Cheever AW, Williams ME et al. IL-10 regulates liver pathology in acute murine *Schistosomiasis mansoni* but is not required for immune down-modulation of chronic disease. *J Immunol* 1998; 160(9):4473-4480.
11. de Waal Malefyt R, Haanen J, Spits H et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. *J Exp Med* Oct 1 1991; 174(4):915-924.
12. Fiorentino DF, Zlotnik A, Vieira P et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. *J Immunol* 1991; 146(10):3444-3451.
13. Tan JC, Braun S, Rong H et al. Characterization of recombinant extracellular domain of human interleukin-10 receptor. *J Biol Chem* May 26 1995; 270(21):12906-12911.
14. Liu Y, Wei SH, Ho AS et al. Expression cloning and characterization of a human IL-10 receptor. *J Immunol* Feb 15 1994; 152(4):1821-1829.
15. Moore KW, de Waal Malefyt R, Coffman RL et al. Interleukin-10 and the interleukin-10 receptor. *Annu Rev Immunol* 2001; 19:683-765.
16. de Waal Malefyt R, Figdor CG, Huijbens R et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN- γ or IL-10. *J Immunol* Dec 1 1993; 151(11):6370-6381.

17. Robinson DS, O'Garra A. Further checkpoints in Th1 development. *Immunity* Jun 2002; 16(6):755-758.
18. De Smedt T, Van Mechelen M, De Becker G et al. Effect of interleukin-10 on dendritic cell maturation and function. *Eur J Immunol* May 1997; 27(5):1229-1235.
19. Berkman N, John M, Roeseams G et al. Inhibition of macrophage inflammatory protein-1 alpha expression by IL-10. Differential sensitivities in human blood monocytes and alveolar macrophages. *J Immunol* Nov 1 1995; 155(9):4412-4418.
20. Kopydlowski KM, Salkowski CA, Cody MJ et al. Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. *J Immunol* Aug 1 1999; 163(3):1537-1544.
21. Jenkins JK, Malyak M, Arend WP. The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 beta production in human monocytes and neutrophils. *Lymphokine Cytokine Res* Feb 1994; 13(1):47-54.
22. D'Amico G, Frascaroli G, Bianchi G et al. Uncoupling of inflammatory chemokine receptors by IL-10: Generation of functional decoys. *Nat Immunol* Nov 2000; 1(5):387-391.
23. Hart PH, Hunt EK, Bonder CS et al. Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. *J Immunol* Oct 15 1996; 157(8):3672-3680.
24. Joyce DA, Steer JH. IL-4, IL-10 and IFN- γ have distinct, but interacting, effects on differentiation-induced changes in TNF- α and TNF receptor release by cultured human monocytes. *Cytokine* Jan 1996; 8(1):49-57.
25. Iwasaki A, Kelsall BL. Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells. *J Exp Med* Jul 19 1999; 190(2):229-239.
26. Khanna A, Morelli AE, Zhong C et al. Effects of liver-derived dendritic cell progenitors on Th1- and Th2-like cytokine responses in vitro and in vivo. *J Immunol* Feb 1 2000; 164(3):1346-1354.
27. Maldonado-Lopez R, Maliszewski C, Urbain J et al. Cytokines regulate the capacity of CD8 α^+ and CD8 α^- dendritic cells to prime Th1/Th2 cells in vivo. *J Immunol* Oct 15 2001; 167(8):4345-4350.
28. Bliss SK, Alcaraz A, Appleton JA. IL-10 prevents liver necrosis during murine infection with *Trichinella spiralis*. *J Immunol* Sep 15 2003; 171(6):3142-3147.
29. Corinti S, Albanesi C, la Sala A et al. Regulatory activity of autocrine IL-10 on dendritic cell functions. *J Immunol* Apr 1 2001; 166(7):4312-4318.
30. Wakkach A, Fournier N, Brun V et al. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. *Immunity* May 2003; 18(5):605-617.
31. Del Prete G, De Carli M, Almerigogna F et al. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. *J Immunol* Jan 15 1993; 150(2):353-360.
32. Svetic A, Jian YC, Lu P et al. *Brucella abortus* induces a novel cytokine gene expression pattern characterized by elevated IL-10 and IFN- γ in CD4 $^+$ T cells. *Int Immunol* Aug 1993; 5(8):877-883.
33. Pohl-Koppe A, Balashov KE, Steere AC et al. Identification of a T cell subset capable of both IFN- γ and IL-10 secretion in patients with chronic *Borrelia burgdorferi* infection. *J Immunol* Feb 15 1998; 160(4):1804-1810.
34. Belkaid Y, Hoffmann KF, Mendez S et al. The role of interleukin (IL)-10 in the persistence of *Leishmania major* in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. *J Exp Med* Nov 19 2001; 194(10):1497-1506.
35. Jankovic D, Kullberg MC, Hieny S et al. In the absence of IL-12, CD4 $^+$ T cell responses to intracellular pathogens fail to default to a Th2 pattern and are host protective in an IL-10 $^{-/-}$ setting. *Immunity* Mar 2002; 16(3):429-439.
36. Castro AG, Neighbors M, Hurst SD et al. Anti-interleukin 10 receptor monoclonal antibody is an adjuvant for T helper cell type 1 responses to soluble antigen only in the presence of lipopolysaccharide. *J Exp Med* Nov 20 2000; 192(10):1529-1534.
37. Igietsme JU, Ananaba GA, Bolier J et al. Suppression of endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for specific Th1 induction: Potential for cellular vaccine development. *J Immunol* Apr 15 2000; 164(8):4212-4219.
38. Hoffmann KF, Wynn TA, Dunne DW. Cytokine-mediated host responses during schistosome infections; walking the fine line between immunological control and immunopathology. *Adv Parasitol* 2002; 52:265-307.
39. Wilson RA, Coulson PS, Dixon B. Migration of the schistosomula of *Schistosoma mansoni* in mice vaccinated with radiation-attenuated cercariae, and normal mice: An attempt to identify the timing and site of parasite death. *Parasitology* 1986; 92(Pt 1):101-116.

40. Ramaswamy K, Kumar P, He YX. A role for parasite-induced PGE2 in IL-10-mediated host immunoregulation by skin stage schistosomula of *Schistosoma mansoni*. *J Immunol* Oct 15 2000; 165(8):4567-4574.
41. Angeli V, Faveuw C, Roye O et al. Role of the parasite-derived prostaglandin D2 in the inhibition of epidermal Langerhans cell migration during schistosomiasis infection. *J Exp Med* May 21 2001; 193(10):1135-1147.
42. He YX, Chen L, Ramaswamy K. *Schistosoma mansoni*, *S. haematobium*, and *S. japonicum*: Early events associated with penetration and migration of schistosomula through human skin. *Exp Parasitol* Oct 2002; 102(2):99-108.
43. Betts CJ, Wilson RA. Th1 cytokine mRNA expression dominates in the skin-draining lymph nodes of C57BL/6 mice following vaccination with irradiated *Schistosoma mansoni* cercariae, but is down-regulated upon challenge infection. *Immunology* Jan 1998; 93(1):49-54.
44. Hoffmann KF, James SL, Cheever AW et al. Studies with double cytokine-deficient mice reveal that highly polarized Th1- and Th2-type cytokine and antibody responses contribute equally to vaccine-induced immunity to *Schistosoma mansoni*. *J Immunol* 1999; 163(2):927-938.
45. van den Biggelaar AH, Borrmann S, Kremsner P et al. Immune responses induced by repeated treatment do not result in protective immunity to *Schistosoma haematobium*: Interleukin (IL)-5 and IL-10 responses. *J Infect Dis* Nov 15 2002; 186(10):1474-1482.
46. Okano M, Satoskar AR, Nishizaki K et al. Lacto-N-fucopentaose III found on *Schistosoma mansoni* egg antigens functions as adjuvant for proteins by inducing Th2-type response. *J Immunol* 2001; 167(1):442-450.
47. van der Kleij D, Latz E, Brouwers JF et al. A novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarization. *J Biol Chem* Dec 13 2002; 277(50):48122-48129.
48. Van der Kleij D, Van Remoortere A, Schuitemaker JH et al. Triggering of innate immune responses by schistosome egg glycolipids and their carbohydrate epitope GalNAc beta 1-4(Fuc alpha 1-2Fuc alpha 1-3)GlcNAc. *J Infect Dis* 2002; 185(4):531-539.
49. Velupillai P, Harn DA. Oligosaccharide-specific induction of interleukin 10 production by B220⁺ cells from schistosome-infected mice: A mechanism for regulation of CD4⁺ T-cell subsets. *Proc Natl Acad Sci USA* 1994; 91(1):18-22.
50. Carneiro-Santos P, Alves-Oliveira LF, Correa-Oliveira R et al. P38 mitogen-activated protein kinase influence on the production of IL-10 in human schistosomiasis mansoni. *Parasite Immunol* Sep-Oct 2002; 24(9-10):493-497.
51. Sher A, Fiorentino D, Caspar P et al. Production of IL-10 by CD4⁺ T lymphocytes correlates with down-regulation of Th1 cytokine synthesis in helminth infection. *J Immunol* 1991; 147(8):2713-2716.
52. Malaquias LC, Falcao PL, Silveira AM et al. Cytokine regulation of human immune response to *Schistosoma mansoni*: Analysis of the role of IL-4, IL-5 and IL-10 on peripheral blood mononuclear cell responses. *Scand J Immunol* 1997; 46(4):393-398.
53. King CL, Medhat A, Malhotra I et al. Cytokine control of parasite-specific anergy in human urinary schistosomiasis. IL-10 modulates lymphocyte reactivity. *J Immunol* 1996; 156(12):4715-4721.
54. Montenegro SM, Miranda P, Mahanty S et al. Cytokine production in acute versus chronic human Schistosomiasis mansoni: The cross-regulatory role of interferon-gamma and interleukin-10 in the responses of peripheral blood mononuclear cells and splenocytes to parasite antigens. *J Infect Dis* 1999; 179(6):1502-1514.
55. Flores-Villanueva PO, Zheng XX, Strom TB et al. Recombinant IL-10 and IL-10/Fc treatment down-regulate egg antigen-specific delayed hypersensitivity reactions and egg granuloma formation in schistosomiasis. *J Immunol* 1996; 156(9):3315-3320.
56. Araujo MI, de Jesus AR, Bacellar O et al. Evidence of a T helper type 2 activation in human schistosomiasis. *Eur J Immunol* Jun 1996; 26(6):1399-1403.
57. Falcao PL, Malaquias LC, Martins-Filho OA et al. Human Schistosomiasis mansoni: IL-10 modulates the in vitro granuloma formation. *Parasite Immunol* 1998; 20(10):447-454.
58. Rezende SA, Silva-Teixeira DN, Drummond SC et al. IL-10 plays a role in the modulation of human granulomatous hypersensitivity against *Schistosoma mansoni* eggs induced by immune complexes. *Scand J Immunol* Jul 1997; 46(1):96-102.
59. Hoffmann KF, Cheever AW, Wynn TA. IL-10 and the dangers of immune polarization: Excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. *J Immunol* 2000; 164(12):6406-6416.
60. Bosshardt SC, Freeman Jr GL, Secor WE et al. IL-10 deficit correlates with chronic, hypersplenomegaly syndrome in male CBA/J mice infected with *Schistosoma mansoni*. *Parasite Immunol* 1997; 19(8):347-353.

61. Brunet LR, Finkelman FD, Cheever AW et al. IL-4 protects against TNF- α -mediated cachexia and death during acute schistosomiasis. *J Immunol* 1997; 159(2):777-785.
62. Fallon PG, Dunne DW. Tolerization of mice to *Schistosoma mansoni* egg antigens causes elevated type 1 and diminished type 2 cytokine responses and increased mortality in acute infection. *J Immunol* 1999; 162(7):4122-4132.
63. Fallon PG, Richardson EJ, Smith P et al. Elevated type 1, diminished type 2 cytokines and impaired antibody response are associated with hepatotoxicity and mortalities during *Schistosoma mansoni* infection of CD4-depleted mice. *Eur J Immunol* 2000; 30(2):470-480.
64. Marshall AJ, Brunet LR, van Gessel Y et al. *Toxoplasma gondii* and *Schistosoma mansoni* synergize to promote hepatocyte dysfunction associated with high levels of plasma TNF- α and early death in C57BL/6 mice. *J Immunol* 1999; 163(4):2089-2097.
65. Rutitzky LI, Hernandez HJ, Stadecker MJ. Th1-polarizing immunization with egg antigens correlates with severe exacerbation of immunopathology and death in schistosome infection. *Proc Natl Acad Sci USA* 2001; 98(23):13243-13248.
66. Chiaramonte MG, Mentink-Kane M, Jacobson BA et al. Regulation and function of the interleukin 13 receptor α 2 during a T helper cell type 2-dominant immune response. *J Exp Med*. Mar 17 2003; 197(6):687-701.
67. Maizels RM, Yazdanbakhsh M. Immune regulation by helminth parasites: Cellular and molecular mechanisms. *Nat Rev Immunol* Sep 2003; 3(9):733-744.
68. King CL, Malhotra I, Mungai P et al. *Schistosoma haematobium*-induced urinary tract morbidity correlates with increased tumor necrosis factor- α and diminished interleukin-10 production. *J Infect Dis* 2001; 184(9):1176-1182.
69. Booth M, Mwatha JK, Joseph S et al. Peri-portal fibrosis in human *Schistosoma mansoni* infection is associated with low IL-10, low IFN γ , high TNF-alpha or low RANTES, depending on age and gender. Submitted 2003.
70. Schopf LR, Hoffmann KF, Cheever AW et al. IL-10 is critical for host resistance and survival during gastrointestinal helminth infection. *J Immunol*. Mar 1 2002; 168(5):2383-2392.
71. Helmby H, Grecnis RK. Contrasting roles for IL-10 in protective immunity to different life cycle stages of intestinal nematode parasites. *Eur J Immunol* Sep 2003; 33(9):2382-2390.
72. van den Biggelaar AH, van Ree R, Rodrigues LC et al. Decreased atopy in children infected with *Schistosoma haematobium*: A role for parasite-induced interleukin-10. *Lancet* 2000; 356(9243):1723-1727.
73. Fickenscher H, Hor S, Kupers H et al. The interleukin-10 family of cytokines. *Trends Immunol* 2002; 23(2):89-96.
74. Heinzl FP, Sadick MD, Mutha SS et al. Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4⁺ lymphocytes in vivo during healing and progressive murine leishmaniasis. *Proc Natl Acad Sci USA* Aug 15 1991; 88(16):7011-7015.
75. Silva JS, Morrissey PJ, Grabstein KH et al. Interleukin 10 and interferon γ regulation of experimental *Trypanosoma cruzi* infection. *J Exp Med* Jan 1 1992; 175(1):169-174.
76. Gazzinelli RT, Eltoun I, Wynn TA et al. Acute cerebral toxoplasmosis is induced by in vivo neutralization of TNF- α and correlates with the down-regulated expression of inducible nitric oxide synthase and other markers of macrophage activation. *J Immunol* Oct 1 1993; 151(7):3672-3681.
77. Hunter CA, Abrams JS, Beaman MH et al. Cytokine mRNA in the central nervous system of SCID mice infected with *Toxoplasma gondii*: Importance of T-cell-independent regulation of resistance to *T. gondii*. *Infect Immun* Oct 1993; 61(10):4038-4044.
78. Belkaid Y, Piccirillo CA, Mendez S et al. CD4⁺CD25⁺ regulatory T cells control *Leishmania* major persistence and immunity. *Nature* Dec 5 2002; 420(6915):502-507.
79. Kane MM, Mosser DM. The role of IL-10 in promoting disease progression in leishmaniasis. *J Immunol* Jan 15 2001; 166(2):1141-1147.
80. Brodskyn C, Patricio J, Oliveira R et al. Glycoinositolphospholipids from *Trypanosoma cruzi* interfere with macrophages and dendritic cell responses. *Infect Immun* Jul 2002; 70(7):3736-3743.
81. Vieth M, Will A, Schroppe K et al. Interleukin-10 inhibits antimicrobial activity against *Leishmania* major in murine macrophages. *Scand J Immunol* Oct 1994; 40(4):403-409.
82. Gazzinelli RT, Oswald IP, James SL et al. IL-10 inhibits parasite killing and nitrogen oxide production by IFN- γ -activated macrophages. *J Immunol* 1992; 148(6):1792-1796.
83. Chakkalath HR, Titus RG. *Leishmania* major-parasitized macrophages augment Th2-type T cell activation. *J Immunol* Nov 15 1994; 153(10):4378-4387.
84. Holscher C, Mohrs M, Dai WJ et al. Tumor necrosis factor α -mediated toxic shock in *Trypanosoma cruzi*-infected interleukin 10-deficient mice. *Infect Immun* Jul 2000; 68(7):4075-4083.
85. Suzuki Y, Sher A, Yap G et al. IL-10 is required for prevention of necrosis in the small intestine and mortality in both genetically resistant BALB/c and susceptible C57BL/6 mice following peroral infection with *Toxoplasma gondii*. *J Immunol* May 15 2000; 164(10):5375-5382.

86. Aliberti JC, Souto JT, Marino AP et al. Modulation of chemokine production and inflammatory responses in interferon- γ and tumor necrosis factor-R1-deficient mice during *Trypanosoma cruzi* infection. *Am J Pathol* Apr 2001; 158(4):1433-1440.
87. Silva JS, Twardzik DR, Reed SG. Regulation of *Trypanosoma cruzi* infections in vitro and in vivo by transforming growth factor beta (TGF- β). *J Exp Med* Sep 1 1991; 174(3):539-545.
88. Gazzinelli RT, Oswald IP, Hieny S et al. The microbicidal activity of interferon- γ -treated macrophages against *Trypanosoma cruzi* involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor- β . *Eur J Immunol* Oct 1992; 22(10):2501-2506.
89. Li J, Hunter CA, Farrell JP. Anti-TGF- β treatment promotes rapid healing of *Leishmania major* infection in mice by enhancing in vivo nitric oxide production. *J Immunol* Jan 15 1999; 162(2):974-979.
90. Langermans JA, Nibbering PH, Van Vuren et al. Transforming growth factor- β suppresses interferon- γ -induced toxoplasmastatic activity in murine macrophages by inhibition of tumour necrosis factor- α production. *Parasite Immunol* Apr 2001; 23(4):169-175.
91. Farrell JP, Kirkpatrick CE. Experimental cutaneous leishmaniasis. II ed. A possible role for prostaglandins in exacerbation of disease in *Leishmania major*-infected BALB/c mice. *J Immunol* Feb 1 1987; 138(3):902-907.
92. Celentano AM, Gorelik G, Solana ME et al. PGE2 involvement in experimental infection with *Trypanosoma cruzi* subpopulations. *Prostaglandins* Mar 1995; 49(3):141-153.
93. Milano S, Arcoleo F, Dieli M et al. Ex vivo evidence for PGE2 and LTB4 involvement in cutaneous leishmaniasis: Relation with infection status and cytokine production. *Parasitology* Jan 1996; 112(Pt 1):13-19.
94. Pinge-Filho P, Tadokoro CE, Abrahamsohn IA. Prostaglandins mediate suppression of lymphocyte proliferation and cytokine synthesis in acute *Trypanosoma cruzi* infection. *Cell Immunol*. Apr 10 1999; 193(1):90-98.
95. Burka JF, Flower RJ. Effects of modulators of arachidonic acid metabolism on the synthesis and release of slow-reacting substance of anaphylaxis. *Br J Pharmacol* Jan 1979; 65(1):35-41.
96. Reis e Sousa C, Yap G, Schulz O et al. Paralysis of dendritic cell IL-12 production by microbial products prevents infection-induced immunopathology. *Immunity* Nov 1999; 11(5):637-647.
97. Aliberti J, Hieny S, Reis e Sousa C et al. Lipoxin-mediated inhibition of IL-12 production by DCs: A mechanism for regulation of microbial immunity. *Nat Immunol* Jan 2002; 3(1):76-82.
98. Aliberti J, Serhan C, Sher A. Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in *Toxoplasma gondii* infection. *J Exp Med* Nov 4 2002; 196(9):1253-1262.
99. Flynn JL, Chan J. Immunology of tuberculosis. *Annu Rev Immunol* 2001; 19:93-129.
100. Manca C, Tsenova L, Barry 3rd CE et al. *Mycobacterium tuberculosis* CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. *J Immunol* Jun 1 1999; 162(11):6740-6746.
101. Turner J, Gonzalez-Juarrero M, Ellis DL et al. In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. *J Immunol* Dec 1 2002; 169(11):6343-6351.
102. Jung YJ, Ryan L, LaCourse R et al. Increased interleukin-10 expression is not responsible for failure of T helper 1 immunity to resolve airborne *Mycobacterium tuberculosis* infection in mice. *Immunology* Jun 2003; 109(2):295-299.
103. Flesch IE, Kaufmann SH. Role of macrophages and alpha beta T lymphocytes in early interleukin 10 production during *Listeria monocytogenes* infection. *Int Immunol* 1994; 6(3):463-468.
104. Demangel C, Bertolino P, Britton WJ. Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production. *Eur J Immunol* 2002; 32(4):994-1002.
105. Hickman SP, Chan J, Salgame P. *Mycobacterium tuberculosis* induces differential cytokine production from dendritic cells and macrophages with divergent effects on naive T cell polarization. *J Immunol* May 1 2002; 168(9):4636-4642.
106. Lyadova IV, Eruslanov EB, Khaidukov SV et al. Comparative analysis of T lymphocytes recovered from the lungs of mice genetically susceptible, resistant, and hyperresistant to *Mycobacterium tuberculosis*-triggered disease. *J Immunol* 2000; 165(10):5921-5931.
107. Feng CG, Kullberg MC, Jankovic D et al. Transgenic mice expressing human interleukin-10 in the antigen-presenting cell compartment show increased susceptibility to infection with *Mycobacterium avium* associated with decreased macrophage effector function and apoptosis. *Infect Immun* Dec 2002; 70(12):6672-6679.

108. Gerosa F, Nisii C, Righetti S et al. CD4⁺ T cell clones producing both interferon- γ and interleukin-10 predominate in bronchoalveolar lavages of active pulmonary tuberculosis patients. *Clin Immunol* 1999; 92(3):224-234.
109. Lyadova I, Yeremeev V, Majorov K et al. An ex vivo study of T lymphocytes recovered from the lungs of I/St mice infected with and susceptible to *Mycobacterium tuberculosis*. *Infect Immun* 1998; 66(10):4981-4988.
110. Rook GA, Steele J, Ainsworth M et al. Activation of macrophages to inhibit proliferation of *Mycobacterium tuberculosis*: Comparison of the effects of recombinant gamma-interferon on human monocytes and murine peritoneal macrophages. *Immunology* Nov 1986; 59(3):333-338.
111. Flesch I, Kaufmann SH. *Mycobacterium tuberculosis* growth inhibition by interferon- γ -activated bone marrow macrophages and differential susceptibility among strains of *Mycobacterium tuberculosis*. *J Immunol* Jun 15 1987; 138(12):4408-4413.
112. Flesch IE, Kaufmann SH. Activation of tuberculostatic macrophage functions by gamma interferon, interleukin-4, and tumor necrosis factor. *Infect Immun* Aug 1990; 58(8):2675-2677.
113. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. *J Immunol* Oct 1 1988; 141(7):2407-2412.
114. Flesch IE, Hess JH, Oswald IP et al. Growth inhibition of *Mycobacterium bovis* by IFN- γ stimulated macrophages: Regulation by endogenous tumor necrosis factor- α and by IL-10. *Int Immunol* 1994; 6(5):693-700.
115. Rojas M, Olivier M, Gros P et al. TNF- α and IL-10 modulate the induction of apoptosis by virulent *Mycobacterium tuberculosis* in murine macrophages. *J Immunol* May 15 1999; 162(10):6122-6131.
116. Balcewicz-Sablinska MK, Keane J, Kornfeld H et al. Pathogenic *Mycobacterium tuberculosis* evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF- α . *J Immunol* 1998; 161(5):2636-2641.
117. Balcewicz-Sablinska MK, Gan H, Remold HG. Interleukin 10 produced by macrophages inoculated with *Mycobacterium avium* attenuates mycobacteria-induced apoptosis by reduction of TNF- α activity. *J Infect Dis* 1999; 180(4):1230-1237.
118. Fratazzi C, Arbeit RD, Carini C et al. Macrophage apoptosis in mycobacterial infections. *J Leukocyte Biol* 1999; 66(5):763-764.
119. Schaible UE, Winau F, Sieling PA et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. *Nat Med* Aug 2003; 9(8):1039-1046.
120. Murray PJ. Defining the requirements for immunological control of mycobacterial infections. *Trends Microbiol* 1999; 7(9):366-372.
121. Redpath S, Ghazal P, Gascoigne NR. Hijacking and exploitation of IL-10 by intracellular pathogens. *Trends Microbiol* 2001; 9(2):86-92.
122. Trinchieri G. Regulatory role of T cells producing both interferon γ and interleukin 10 in persistent infection. *J Exp Med* 2001; 194(10):F53-57.
123. Bermudez LE, Champi J. Infection with *Mycobacterium avium* induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice. *Infect Immun* 1993; 61(7):3093-3097.
124. Denis M, Ghadirian E. IL-10 neutralization augments mouse resistance to systemic *Mycobacterium avium* infections. *J Immunol* 1993; 151(10):5425-5430.
125. Roach DR, Martin E, Bean AG et al. Endogenous inhibition of antimycobacterial immunity by IL-10 varies between mycobacterial species. *Scand J Immunol* 2001; 54(1-2):163-170.
126. Murray PJ, Young RA. Increased antimycobacterial immunity in interleukin-10-deficient mice. *Infect Immun* 1999; 67(6):3087-3095.
127. Jacobs M, Brown N, Allie N et al. Increased resistance to mycobacterial infection in the absence of interleukin-10. *Immunology* 2000; 100(4):494-501.
128. Erb KJ, Kirman J, Delahunt B et al. IL-4, IL-5 and IL-10 are not required for the control of *M. bovis*-BCG infection in mice. *Immunol Cell Biol* 1998; 76(1):41-46.
129. North RJ. Mice incapable of making IL-4 or IL-10 display normal resistance to infection with *Mycobacterium tuberculosis*. *Clin Exp Immunol* 1998; 113(1):55-58.
130. Murray PJ, Wang L, Onufryk C et al. T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. *J Immunol* 1997; 158(1):315-321.
131. Lang R, Rutschman RL, Greaves DR et al. Autocrine deactivation of macrophages in transgenic mice constitutively overexpressing IL-10 under control of the human CD68 promoter. *J Immunol* 2002; 168(7):3402-3411.
132. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. *Annu Rev Immunol* 2002; 20:495-549.

133. Morrissey PJ, Charrier K, Braddy S et al. CD4⁺ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4⁺ T cells. *J Exp Med* 1993; 178(1):237-244.
134. Powrie F, Leach MW, Mauze S et al. Phenotypically distinct subsets of CD4⁺ T cells induce or protect from chronic intestinal inflammation in C B-17 scid mice. *Int Immunol* 1993; 5(11):1461-1471.
135. Powrie F, Correa-Oliveira R, Mauze S et al. Regulatory interactions between CD45RB^{high} and CD45RB^{low} CD4⁺ T cells are important for the balance between protective and pathogenic cell-mediated immunity. *J Exp Med* 1994; 179(2):589-600.
136. Read S, Malmström V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25⁺CD4⁺ regulatory cells that control intestinal inflammation. *J Exp Med* 2000; 192(2):295-302.
137. Powrie F, Leach MW, Mauze S et al. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RB^{hi} CD4⁺ T cells. *Immunity* 1994; 1(7):553-562.
138. Asseman C, Mauze S, Leach MW et al. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. *J Exp Med* 1999; 190(7):995-1004.
139. Hagenbaugh A, Sharma S, Dubinett SM et al. Altered immune responses in interleukin 10 transgenic mice. *J Exp Med* 1997; 185(12):2101-2110.
140. Berg DJ, Davidson N, Kühn R et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4⁺ TH1-like responses. *J Clin Invest* 1996; 98(4):1010-1020.
141. Duchmann R, Schmitt E, Knolle P et al. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. *Eur J Immunol* 1996; 26(4):934-938.
142. Kullberg MC, Jankovic D, Gorelick PL et al. Bacteria-triggered CD4⁺ T regulatory cells suppress *Helicobacter hepaticus*-induced colitis. *J Exp Med* Aug 19 2002; 196(4):505-515.
143. Maloy KJ, Salaun L, Cahill R et al. CD4⁺CD25⁺ T_R cells suppress innate immune pathology through cytokine-dependent mechanisms. *J Exp Med* Jan 6 2003; 197(1):111-119.
144. Asseman C, Read S, Powrie F. Colitogenic Th1 Cells are present in the antigen-experienced T cell pool in normal mice: Control by CD4⁺ regulatory T cells and IL-10. *J Immunol* Jul 15 2003; 171(2):971-978.
145. Kullberg MC, Ward JM, Gorelick PL et al. *Helicobacter hepaticus* triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferon-dependent mechanism. *Infect Immun* 1998; 66(11):5157-5166.
146. Mizoguchi A, Mizoguchi E, Takedatsu H et al. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. *Immunity* Feb 2002; 16(2):219-230.
147. Annacker O, Burlen-Defranoux O, Pimenta-Araujo R et al. Regulatory CD4 T cells control the size of the peripheral activated/memory CD4 T cell compartment. *J Immunol* 2000; 164(7):3573-3580.
148. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O et al. CD25⁺ CD4⁺ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. *J Immunol* 2001; 166(5):3008-3018.
149. Willems F, Marchant A, Delville JP et al. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. *Eur J Immunol* Apr 1994; 24(4):1007-1009.
150. Groux H, O'Garra A, Bigler M et al. A CD4⁺ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. *Nature* 1997; 389(6652):737-742.
151. Takeda K, Clausen BE, Kaisho T et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. *Immunity* 1999; 10(1):39-49.
152. Powrie F, Carlino J, Leach MW et al. A critical role for transforming growth factor- β but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB^{low} CD4⁺ T cells. *J Exp Med* 1996; 183(6):2669-2674.
153. Neurath MF, Fuss I, Kelsall BL et al. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. *J Exp Med* Jun 1 1996; 183(6):2605-2616.
154. Kitani A, Fuss IJ, Nakamura K et al. Treatment of experimental (Trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)- β 1 plasmid: TGF- β 1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor beta2 chain downregulation. *J Exp Med* 2000; 192(1):41-52.
155. Fuss IJ, Boirivant M, Lacy B et al. The interrelated roles of TGF- β and IL-10 in the regulation of experimental colitis. *J Immunol* 2002; 168(2):900-908.
156. Cottrez F, Groux H. Regulation of TGF-beta response during T cell activation is modulated by IL-10. *J Immunol* Jul 15 2001; 167(2):773-778.

157. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. *Am J Gastroenterol* 1997; 92(12 Suppl):5S-11S.
158. Gionchetti P, Rizzello F, Venturi A et al. Review—antibiotic treatment in inflammatory bowel disease: Rifaximin, a new possible approach. *Eur Rev Med Pharmacol Sci* 1999; 3(1):27-30.
159. Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: New insight to pathogenesis or a possible therapeutic alternative? *Gastroenterology* 1999; 116(5):1246-1249.
160. Khoo UY, Proctor IE, Macpherson AJ. CD4⁺ T cell down-regulation in human intestinal mucosa: Evidence for intestinal tolerance to luminal bacterial antigens. *J Immunol* 1997; 158(8):3626-3634.
161. Duchmann R, Kaiser I, Hermann E et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). *Clin Exp Immunol* 1995; 102(3):448-455.
162. Braat H, Peppelenbosch MP, Hommes DW. Interleukin-10-based therapy for inflammatory bowel disease. *Expert Opin Biol Ther* Aug 2003; 3(5):725-731.
163. Steidler L, Hans W, Schotte L et al. Treatment of murine colitis by *Lactococcus lactis* secreting interleukin-10. *Science* Aug 25 2000; 289(5483):1352-1355.